Navigation Links
MonoSol Rx to Present at the 20th Annual Piper Jaffray Health Care Conference
Date:11/26/2008

WARREN, N.J.,Nov. 26 /PRNewswire-FirstCall/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, today announced that A. Mark Schobel, president and CEO, and Keith J. Kendall, executive vice president and CFO, are scheduled to present at the 20th Annual Piper Jaffray Health Care Conference to be held December 2-3, 2008 at the New York Palace in New York City.

    Event:  20th Annual Piper Jaffray Health Care Conference
    Date:   Wednesday, December 3, 2008
    Time:   9:50 a.m. ET

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm(R) technology to deliver prescription drugs in quick dissolving films. PharmFilm(R) is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company is a leader in thin film drug delivery and has a strong intellectual property position, a portfolio of commercialized OTC drug products, and a pipeline of prescription formulations utilizing its PharmFilm(R) technology. With a vertically integrated development and production infrastructure, MonoSol Rx has the capacity to manufacture prescription and OTC drug products for near, mid and long-term revenues.

The Company's commercialization strategy for all PharmFilm(R) products is to partner with the innovator or other specialty pharma or leading consumer products companies who have the core competency to sell-in and manage the sales and marketing of the products. For the Company's existing and future partners, PharmFilm(R) formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm(R) is also a tool to help sales and marketing partners differentiate in competitive markets while offering
'/>"/>

SOURCE MonoSol Rx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Strativa Pharmaceuticals Acquires Commercialization Rights to Thin Film Formulation of Ondansetron From MonoSol Rx
2. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
3. MonoSol Rx Names Vincent Viviani Senior Vice President, Manufacturing and Operations
4. MonoSol Rx Granted US Patent for Thin Film Manufacturing Process
5. Critical Homecare Solutions Holdings, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
6. Healthcare Partners Medical Group to Host Free Medicare Benefits Presentations
7. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
8. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
9. Alexion to Present at the 20th Annual Piper Jaffray Health Care Conference
10. CVS Caremark Presents Influenza Vaccine Data at Rescheduled 2008 DMAA Annual Meeting
11. Omnicell to Present at Piper Jaffray 20th Annual Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...uld aid in eventual development of screening test,...3 (HealthDay News) -- New research points to the p... heart disease. , People with high blood pressu...ctivation in the body were found to be twice as li...ve heart failure, the study found. , The findin...
(Date:12/3/2009)..., FREMONT, Calif., Dec. 3 /PRNewswire-USNewswire/...AACR) released findings today from one of the larg...cancer in women conducted by the Northern Califor...aled that women who never smoked cigarettes and wh...a lifetime--especially during adulthood--had a sig...
(Date:12/3/2009)..., LA JOLLA, Calif., Dec. 3 /PRNewswire-USNewswi...e for Biological Studies unanimously voted to ele... La Jolla. ,, Fred Dotzler is co-founder and ..., Calif. De Novo is investing $650 million from th...hnology companies. Dotzler founded Medicus Venture...
(Date:12/3/2009)... , PASADENA, Calif., Dec. 3 Fo...nesses, the risk of disability remains one of the ...l financial well being, but also their business,s ...lines have taken their toll, owners of small busin...inancial safety net with enhanced disability cover...
(Date:12/3/2009)..., SARASOTA, Fla., Dec. 3 If you...ary, get ready for a stunning look at the other si...a Norwood will screen her feature documentary, "Su...n Tuesday, December 8th, 5 p.m. at Sever Hall, Har...arged Living" College Tour. The film will be follo...
Breaking Medicine News(10 mins):Health News:Vitamin D May Be Tied to Heart Disease Via Genes 2Health News:Northern California Cancer Center's Findings on Breast Cancer and Secondhand Smoke Released Internationally by the American Association for Cancer Research 2Health News:Salk Institute Board of Trustees Elects Leaders in Venture Capital and Publishing to its Membership 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 3Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 4Health News:Jenna Norwood to Present Award-Winning Documentary & Lecture at Harvard University 2
...Diego Palacio Betancourt, presented Childrens Hosp...the Division of Cardiac Intensive Care Ricardo A. ...ejarano Civic Cross Medal. , During a visit to th...ding achievements and contributions to the medical...
...ess for Better Health with,Innovative ,Sleep and C...ss, FORT LAUDERDALE, Fla., Jan. 9 Contour Produc...mmends people implement an,ergonomic makeover into...scles people can make the most of their daily,acti...
...ption for the Treatment of ED-, INDIANAPOLIS, Jan... today that the U.S. Food and Drug Administration,...ce daily use (2.5 mg and,5 mg), an oral medication...een doses., Currently available in parts of Europ...
...equity, public offering, private placemen...esents leading clients in gaming, green tech, ente... technology and home construction, LOS ANGELES, J... firm advised on a variety of mergers & acquisitio...
...emia &,Lymphoma Society has organized "Team In Tra...ividuals achieve personal goals and most of all, r...h., (See video from The Leukemia & Lymphoma Socie...a full marathon run (or walk), a 100-mile century,...
...nnounced today that J. Chris Hrouda has been named...he organization,s Biomedical Services., Hrouda wi...ction,organizations. Each year the American Red Cr...nd transfusion centers across,the country. This wo...
Other Medicine News:Health News:Children's doctor honored by president of Colombia for contributions to pediatric cardiac care 2Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 2Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 3Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 2Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 3Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 4Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 5Health News:Irell & Manella Posts Strong Year for Corporate Transactions 2Health News:Irell & Manella Posts Strong Year for Corporate Transactions 3Health News:Irell & Manella Posts Strong Year for Corporate Transactions 4Health News:Irell & Manella Posts Strong Year for Corporate Transactions 5Health News:Irell & Manella Posts Strong Year for Corporate Transactions 6Health News:American Red Cross Announces New Leader for Biomedical Services 2
(Date:12/3/2009)..., , SAN DIEGO, Dec. 3 /PRNewswire-FirstC...nnounced today that it has entered into a new leas...EGN ) for approximately 131,000 square feet of add...pace at The Landmark at Eastview campus in Tarryto...23. This lease of additional space was completed a...
(Date:12/3/2009)..., , HOERSHOLM, Denmark and S...,, - SPC3649 Successfully Inhibits miR-122,...ation, Thereby Significantly Reducing Hepatitis C,...y Infected With the,Hepatitis C Virus , -... Viral Resistance and,No Serious Adverse Events in...
(Date:12/3/2009)..., , COSTA MESA, Calif., Dec. 3 /PRNewswire...re on-Demand Printing Solutions, announces the ad...s line of secure prescription printing solutions. ...series, TROY,s 3015 SecureRx(TM) Printers provide ...aserJet workgroup printing capability and enhanced...
Breaking Medicine Technology:BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5New TROY SecureRx Prescription Printer Marks 50th Hospital Installation Milestone 2Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 1Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 2Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 3Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 4Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 5Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5 ZFP Therapeutic to Treat HIV AIDS 5037 6Oxygen Biotherapeutics Inc Receives Phase II Trial Approval in Israel 5033 1Oxygen Biotherapeutics Inc Receives Phase II Trial Approval in Israel 5033 2Study reveals 2 3 of prostate cancer patients do not need treatment 58130 1Study reveals 2 3 of prostate cancer patients do not need treatment 58130 2
... Findings Show Cystic Fibrosis Patients Cough More... -, SOUTH PLAINFIELD, N.J., May 21 PTC Th...ggesting that the quantification of cough,frequenc...e in cystic,fibrosis (CF). Cough is one of the mos...s in CF. According to data presented today at the,...
... Data Presented at American Urological Association... 21 Researchers,from Dendreon Corporation (Nasdaq...rating the potential of D-3263, Dendreon,s orally ...(a transmembrane cation channel protein also,known... (BPH)., The abstract (#2041), "Preclinical Valid...
Other Medicine Technology:PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis 2PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis 3PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis 4Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 2Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 3Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 4
MBP 1000GGenomic Tip
Tipack (Sterilized) DL10
Finntip BioCon
Finntip Filter Tips, 1500 L
Medicine Products: